These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 32929059)

  • 21. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
    Cheng YY; Kirschner MB; Cheng NC; Gattani S; Klebe S; Edelman JJ; Vallely MP; McCaughan BC; Jin HC; van Zandwijk N; Reid G
    J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.
    Andersen M; Trapani D; Ravn J; Sørensen JB; Andersen CB; Grauslund M; Santoni-Rugiu E
    Anticancer Res; 2015 Nov; 35(11):6223-9. PubMed ID: 26504055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.
    Williams M; Kirschner MB; Cheng YY; Hanh J; Weiss J; Mugridge N; Wright CM; Linton A; Kao SC; Edelman JJ; Vallely MP; McCaughan BC; Cooper W; Klebe S; Lin RC; Brahmbhatt H; MacDiarmid J; van Zandwijk N; Reid G
    Oncotarget; 2015 Sep; 6(27):23480-95. PubMed ID: 26125439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequent methylation of the tumour suppressor miR-1258 targeting PDL1: implication in multiple myeloma-specific cytotoxicity and prognostification.
    Wang LQ; Kumar S; Calin GA; Li Z; Chim CS
    Br J Haematol; 2020 Jul; 190(2):249-261. PubMed ID: 32079038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
    Muraoka T; Soh J; Toyooka S; Aoe K; Fujimoto N; Hashida S; Maki Y; Tanaka N; Shien K; Furukawa M; Yamamoto H; Asano H; Tsukuda K; Kishimoto T; Otsuki T; Miyoshi S
    Lung Cancer; 2013 Dec; 82(3):485-90. PubMed ID: 24168922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease.
    Cavalleri T; Angelici L; Favero C; Dioni L; Mensi C; Bareggi C; Palleschi A; Rimessi A; Consonni D; Bordini L; Todaro A; Bollati V; Pesatori AC
    PLoS One; 2017; 12(5):e0176680. PubMed ID: 28472171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MiR-320a inhibits malignant phenotype of melanoma cells via targeting PBX3.
    Fu G; Lu J; Zheng Y; Wang P; Shen Q
    J BUON; 2020; 25(4):2071-2077. PubMed ID: 33099955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
    Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M
    Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions.
    Birnie KA; Prêle CM; Musk AWB; de Klerk N; Lee YCG; Fitzgerald D; Allcock RJN; Thompson PJ; Creaney J; Badrian B; Mutsaers SE
    Dis Markers; 2019; 2019():8628612. PubMed ID: 31481984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
    Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In Silico Transcriptomic Analysis of Wound-Healing-Associated Genes in Malignant Pleural Mesothelioma.
    Rouka E; Beltsios E; Goundaroulis D; Vavougios GD; Solenov EI; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
    Medicina (Kaunas); 2019 Jun; 55(6):. PubMed ID: 31212858
    [No Abstract]   [Full Text] [Related]  

  • 32. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
    J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Signal Transducer and Activator of Transcription 1 (STAT1) Knock-down Induces Apoptosis in Malignant Pleural Mesothelioma.
    Arzt L; Halbwedl I; Gogg-Kamerer M; Popper HH
    Pathol Oncol Res; 2017 Jul; 23(3):595-605. PubMed ID: 27987139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
    Yamamoto K; Seike M; Takeuchi S; Soeno C; Miyanaga A; Noro R; Minegishi Y; Kubota K; Gemma A
    Oncol Rep; 2014 Dec; 32(6):2365-72. PubMed ID: 25231602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of exosomal miR-320a from cancer-associated fibroblasts contributes to HCC proliferation and metastasis.
    Zhang Z; Li X; Sun W; Yue S; Yang J; Li J; Ma B; Wang J; Yang X; Pu M; Ruan B; Zhao G; Huang Q; Wang L; Tao K; Dou K
    Cancer Lett; 2017 Jul; 397():33-42. PubMed ID: 28288874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients.
    Fusco N; Vaira V; Righi I; Sajjadi E; Venetis K; Lopez G; Cattaneo M; Castellani M; Rosso L; Nosotti M; Clerici M; Ferrero S
    Lung Cancer; 2020 Dec; 150():53-61. PubMed ID: 33065463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
    Laszlo V; Hoda MA; Garay T; Pirker C; Ghanim B; Klikovits T; Dong YW; Rozsas A; Kenessey I; Szirtes I; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zöchbauer-Müller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Dome B; Hegedus B
    J Pathol; 2015 Oct; 237(2):203-14. PubMed ID: 26011651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma.
    Schelch K; Kirschner MB; Williams M; Cheng YY; van Zandwijk N; Grusch M; Reid G
    Mol Oncol; 2018 Jan; 12(1):58-73. PubMed ID: 29094504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction.
    Fortunato O; Boeri M; Moro M; Verri C; Mensah M; Conte D; Caleca L; Roz L; Pastorino U; Sozzi G
    Cell Death Dis; 2014 Dec; 5(12):e1564. PubMed ID: 25501825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study.
    Mozzoni P; Ampollini L; Goldoni M; Alinovi R; Tiseo M; Gnetti L; Carbognani P; Rusca M; Mutti A; Percesepe A; Corradi M
    Dis Markers; 2017; 2017():9645940. PubMed ID: 28757678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.